Resources

Myanmar is in a time of unique political and social transition. However, sexual and reproductive health outcomes in Myanmar remain among the poorest in the region.PATH is supporting Myanmar’s Ministry of Health and Sports to develop a new National Sexual and Reproductive Health and Rights Policy that aims to provide an inclusive policy framework to guide subsequent strategic plans, clinical guidelines, care pathways, service standards, and data collection, that take a rights-based approach to sexual and reproductive health service delivery.

Breast cancer is the leading cause of cancer among women worldwide, with over 2 million new cases occurring in 2018. More than 625,000 women die every year from breast cancer. Although mammography is the gold standard for breast cancer detection, due to lack of resources it is not accessible in many LMIC health systems. The good news is that there is an alternative approach that is able to detect cancer at earlier stages and increase women’s chances of being treated and living longer lives. This fact sheet describes how PATH has developed an integrated model for early detection focused on more efficient use of resources that are currently available in low-resource areas.

Subcutaneous DMPA (DMPA-SC, brand name Sayana® Press) is a new, easy-to-use injectable contraceptive that is ideally suited for remote access and even self-injection. This research brief describes new research findings that women who self-injection DMPA-SC continue to use contraception longer than women who use intramuscular DMPA (DMPA-IM, brand name Depo-Provera®) administered by a health worker. For more information, visit www.path.org/dmpa-sc or email FPoptions@path.org.

There is broad recognition of the growing and inequitable burden of cervical cancer in low-resource countries, and uptake of new screening and treatment alternatives for adult women and human papillomavirus (HPV) vaccines for young adolescent girls is on the rise. For the first time in history the elimination of the disease is within reach, and on May 19, 2018, WHO Director-General, Dr. Tedros Adhanom Ghebreyesus made a global call for action on cervical cancer elimination. This fact sheet summarizes PATH's current work and future priorities.

Subcutaneous DMPA (DMPA-SC, Sayana® Press) is a new, easy-to-use injectable contraceptive that is ideally suited for remote access and even self-injection. This brief provides an overview of PATH’s research studies assessing the feasibility and acceptability of self-injection in Uganda and Senegal. For more information, please visit www.path.org/dmpa-sc or email FPoptions@path.org.